Authors
Juan Carlos Del Río-Valencia, Rocío Tamayo-Bermejo, Juan Diego Paradas-Palomo, Beatriz Mora-Rodríguez, Cristina López-Escola
Published in
Farmacia hospitalaria : organo oficial de expresion cientifica de la Sociedad Espanola de Farmacia Hospitalaria. Sep 23, 2026. Epub Sep 23, 2026.
Abstract
The objective of this study was to evaluate the effectiveness and safety of pembrolizumab as monotherapy in patients with Non-Small-Cell Lung Cancer and brain metastases in Real-World clinical practice at Tertiary care.
A retrospective observational study was conducted at a tertiary hospital in Spain between August 2017 and March 2023. Adult patients with stage IV non-small-cell lung carcinoma and radiologically confirmed brain metastases who received pembrolizumab monotherapy were included. Progression-free survival, overall survival, objective response rate and treatment-related adverse events were analyzed.
Among 172 patients treated with pembrolizumab, 45 had brain metastases and 25 received monotherapy. Median progression-free survival was 3 months (95% confidence interval: 2.02-3.97), and median overall survival was 6 months (95% confidence interval: 4.37-7.62). The objective response rate was 24%, and the disease control rate was 40%. Treatment-related toxicity of any grade was reported in 64% of patients, with no unexpected safety signals observed.
Pembrolizumab monotherapy showed clinical activity and an acceptable safety profile in patients with non-small-cell lung carcinoma and brain metastases treated in routine practice. Larger prospective studies are needed to optimize patient selection in this setting.
PMID:
42778497
Bibliographic data and abstract were imported from PubMed on 24 Sep 2026.
Read full publication at:
Please sign in
to see all details.
Advertisement
Stats
- Recommendations n/a n/a positive of 0 vote(s)
- Views 6
- Comments 0